Insider Selling: Liquidia Co. (NASDAQ:LQDA) CEO Sells $100,904.09 in Stock

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 8,053 shares of the business’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $12.53, for a total transaction of $100,904.09. Following the completion of the sale, the chief executive officer now directly owns 818,932 shares in the company, valued at approximately $10,261,217.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Liquidia Trading Down 11.7 %

Shares of NASDAQ LQDA opened at $11.34 on Thursday. The company has a market capitalization of $866.11 million, a P/E ratio of -7.27 and a beta of 0.32. Liquidia Co. has a 12 month low of $5.71 and a 12 month high of $16.99. The stock has a 50 day moving average of $12.71 and a 200-day moving average of $13.44.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.22). The company had revenue of $2.97 million during the quarter, compared to analyst estimates of $4.31 million. Liquidia had a negative net margin of 674.42% and a negative return on equity of 177.83%. Analysts predict that Liquidia Co. will post -1.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Fortitude Family Office LLC acquired a new stake in Liquidia during the fourth quarter worth approximately $26,000. Hilltop National Bank acquired a new stake in Liquidia during the 2nd quarter worth approximately $33,000. Tower Research Capital LLC TRC boosted its stake in Liquidia by 610.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,997 shares of the company’s stock valued at $108,000 after purchasing an additional 7,731 shares during the period. DMC Group LLC acquired a new position in Liquidia in the 2nd quarter valued at $122,000. Finally, Whitcomb & Hess Inc. bought a new position in Liquidia during the 2nd quarter worth $126,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on LQDA. HC Wainwright restated a “buy” rating and set a $32.00 price objective on shares of Liquidia in a research note on Wednesday, July 10th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of Liquidia in a research note on Monday, June 3rd. Finally, Oppenheimer assumed coverage on shares of Liquidia in a research note on Tuesday, June 25th. They issued a “market perform” rating for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $21.60.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).